8-K: Altimmune Announces Positive Progress in Pemvidutide Trials and Reports Year-End Financial Results

Altimmune reports financial results for Q4 and full year 2024, highlighting progress with pemvidutide and upcoming milestones.

Summary

• Altimmune announced its financial results for the fourth quarter and full year ended December 31, 2024.
• Top-line data from the Phase 2b IMPACT trial of pemvidutide in MASH is expected in Q2 2025.
• The company's IND applications for pemvidutide in two additional indications have been cleared by the FDA, with Phase 2 trials expected to begin in mid-2025.
• Altimmune will hold a virtual R&D Day on March 13, 2025, to discuss pemvidutide development.
• The company reported cash, cash equivalents, and short-term investments of $131.9 million as of December 31, 2024.
• The net loss for the year ended December 31, 2024, was $95.1 million, or $1.34 net loss per share.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, FDA clearances, and a strong cash position. However, the net loss and increased R&D expenses temper the overall outlook.

Positives

• The Phase 2b IMPACT trial of pemvidutide in MASH is on track to report top-line data in Q2 2025.
• IND applications for pemvidutide in two additional indications have been cleared by the FDA, with Phase 2 trials expected to begin in mid-2025.
• The company has a strong cash position with $131.9 million in cash, cash equivalents, and short-term investments as of December 31, 2024.
• Two pharmaceutical industry veterans have been added to the Company Board of Directors.

Negatives

• The company reported a net loss of $95.1 million, or $1.34 net loss per share, for the year ended December 31, 2024.
• Research and development expenses increased to $82.2 million for the year ended December 31, 2024, compared to $65.8 million in the same period in 2023.

Risks

• The success of pemvidutide is dependent on positive results from clinical trials, including the IMPACT Phase 2b trial.
• Delays in regulatory review, manufacturing, and supply chain interruptions could impact the development and commercialization of pemvidutide.
• Adverse effects on healthcare systems and disruption of the global economy could impact the company's operations.
• The company's ability to manufacture clinical trial materials on the timelines anticipated is a risk factor.

Future Outlook

Altimmune is focused on advancing pemvidutide in multiple indications, including MASH and obesity, with key milestones including the top-line data readout from the IMPACT Phase 2b trial in Q2 2025 and the initiation of Phase 2 trials in additional indications in mid-2025. The company anticipates holding an end-of-Phase 2 meeting with the FDA by the end of 2025 to discuss the Phase 3 program.

Management Comments

• Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune, stated that 2024 was a year of important progress for Altimmune as they continued to advance pemvidutide in multiple indications.
• Dr. Garg expressed confidence that pemvidutide will achieve statistically significant improvements in biopsy endpoints at trial readout.

Industry Context

Altimmune is operating in the competitive biopharmaceutical industry, focusing on developing treatments for obesity and MASH, which are areas of significant unmet medical need. The company's progress with pemvidutide and its expansion into additional indications positions it to potentially capture a significant share of these markets.

Comparison to Industry Standards

• The document states that with a successful readout from IMPACT, pemvidutide would be the first incretin to achieve statistical significance on MASH resolution and fibrosis improvement at only 24 weeks of treatment.
• The document states that pemvidutide would be the first therapy in any class to achieve these endpoints along with meaningful weight loss at this timepoint.
• Companies like Madrigal Pharmaceuticals (Resmetirom) and Viking Therapeutics (VK2809) are also developing treatments for MASH, and their clinical trial results and regulatory progress will be key benchmarks for Altimmune.

Management Changes

Stakeholder Impact

• Shareholders: The progress of pemvidutide and the company's financial performance will impact shareholder value.
• Employees: The company's growth and development activities will impact employment opportunities and job security.
• Patients: The development of new treatments for obesity and MASH will benefit patients suffering from these conditions.
• The addition of Teri Lawver and Jerry Durso to the Board of Directors will bring additional expertise to the company.

Next Steps

• Report top-line data from the Phase 2b IMPACT trial of pemvidutide in MASH in Q2 2025.
• Initiate Phase 2 trials in additional indications in mid-2025.
• Hold a virtual R&D Day on March 13, 2025.
• Hold an end-of-Phase 2 meeting with the FDA by the end of 2025 to gain alignment on the registrational Phase 3 program.

Key Dates